Nyxoah's Sleep Apnea Device Receives FDA Breakthrough Tag

The FDA has granted Breakthrough Device Designation to Nyxoah SA NYXH Genio bilateral hypoglossal nerve stimulation system.
The system treats adult patients with moderate to severe Obstructive Sleep Apnea (OSA) and Complete Concentric Collapse (CCC) of the soft palate.
Genio system, Nyxoah's lead solution, is patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy.
Related content: Benzinga's Full FDA Calendar.
Price Action: NYXH stock is up 4.30% at $30.22 during the premarket session on the last check Tuesday.